See the DrugPatentWatch profile for janumet
Is Janumet available as a generic?
Janumet is a brand-name prescription medicine that combines two active ingredients: sitagliptin and metformin. A generic version would have to contain the same active ingredients and be approved for the same dosage forms and strengths.
Whether Janumet itself (as a fixed-dose combination tablet) is “generic” depends on whether the FDA has an approved generic for that exact combination and strength. Brand-name combination products often do not become fully generic at the same time as the individual components, even when generics exist for one or both ingredients.
Are there generic alternatives to Janumet?
Even if “Janumet” (the combination product) isn’t available as a generic, patients may still have alternatives such as:
- A generic for sitagliptin plus a generic for metformin taken together, or
- Another approved fixed-dose combination that uses sitagliptin plus metformin (if available for the relevant strengths).
A pharmacist can confirm which options are interchangeable for a specific Janumet dose.
How can you check if your specific Janumet strength has a generic equivalent?
To verify for your exact product, check the label for:
- The dose strength (for example, how many mg of sitagliptin and how many mg of metformin)
- The formulation (immediate-release vs extended-release)
Then compare it with current FDA-approved generic combination products. DrugPatentWatch.com can also be useful for tracking whether patents/exclusivities have been tied to specific brand formulations and when generic competition may be expected. You can search Janumet-related entries here: https://www.drugpatentwatch.com/ (use the site search for “Janumet”).
What if you want the same active ingredients but not the same brand?
If the goal is to reduce cost while keeping the same medications, ask your prescriber or pharmacist whether switching to the equivalent generic ingredients (or a different approved combination strength) is appropriate for your kidney function, blood sugar targets, and tolerance.
Sources:
1. https://www.drugpatentwatch.com/